Evidence map›Paper›PMID 35243117›Full record

ReviewTranslational gastroenterology and hepatology2022

Identifying the pre-malignant stomach: from guidelines to practice.

Jonathan R White, Matthew Banks

Abstract readReview
In one paragraph

Review in Translational gastroenterology and hepatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Exploring the gastric cancer care pathway in South Africa.African journal of primary health care & family medicine · 2025
    Article
  7. Article
  8. Article
  9. Article
  10. Pepsinogen I, pepsinogen II, gastrin-17, andArchives of medical science : AMS · 2024
    Article
  11. Article
  12. Article
  13. Review
  14. Salivary biomarkers for the diagnosis of gastric cancer: a systematic review.Revista cientifica odontologica (Universidad Cientifica del Sur)
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Jonathan R WhiteNIHR Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and the University of Nottingham, Nottingham, UK.
Matthew BanksUniversity College London Hospital, University College London Hospitals NHS Foundation Trust, London, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gastric adenocarcinoma develops after stepwise progression from normal mucosa through to adenocarcinoma most commonly after being triggered by

Indexed as

atrophic gastritisdysplasiaendoscopygastric adenocarcinomaHelicobacter pylori (H. pylori)intestinal metaplasiaPremalignant

Identifiers

PMID35243117
PMCPMC8826400

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.